Amgen Q2 Earnings: Revenue Beat and Guidance Increase

Q2 Earnings Performance

• 📊 Amgen reported Q2 results, beating analyst expectations on both revenue and adjusted EPS.
• 💰 Adjusted EPS came in at $6.62, surpassing the $5.29 estimate.
• 📈 Revenue reached $9.18 billion, exceeding the $8.94 billion consensus.

Drug Performance and Forecast

• 💊 Revenue for the osteoporosis drug Prolia met expectations, despite facing biosimilar competition in the US.
• ⚠️ Weakness was noted in rare disease and cancer drugs, as well as inflammation drugs excluding Otesla.
• 🎯 For the full year, Amgen slightly increased its revenue guidance to $35-$36 billion, up from the previous $35.37 billion estimate.
• 📉 While full-year adjusted EPS guidance is also increasing, the midpoint is slightly lower than analyst expectations.

Future Outlook and Data

• ⚖️ The updated guidance accounts for the impact of implemented tariffs but does not anticipate future pharma-specific tariffs or price adjustments.
• 🔬 Amgen now expects data from Part 2 of its Phase 2 obesity trial in the fourth quarter, a more specific timeline than previously stated.